ClinicalTrials.gov
public full text
Public Domain
Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection
TP-102 is a novel bacteriophage cocktail comprised of 5 (five) lytic bacteriophages against Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii. TP-102 is being developed for topical treatment of patients with wound infections including chronic ulcers; applied every other day (three times weekly (TIW)).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers#878978
- Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic Gastroparesis#854234
- Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers#836101
- Appropriate Strategy of Surgical Treatment in Ischemic Diabetic Foot#383525
- Tele-expertise in Patients With Diabetes Hospitalized for Covid-19 Infection#429712
Record · ID 1093706
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive